MEF2C and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia, repression of miR-223 results in the activation of MEF2C and its downregulation negatively correlates with disease risk (Agatheeswaran et al. 2013; Carrillo et al. 2023).